Literature DB >> 16167516

Incidence of cross resistance between rifampicin and rifabutin in Mycobacterium tuberculosis strains in Izmir, Turkey.

G Senol1, A Erbaycu, A Ozsöz.   

Abstract

Rifabutin is a spiro-piperidyl-rifamycin derived from rifamycin-S. This study was planned to determine the minimal inhibitory concentrations (MICs) of rifabutin and rifampicin against Mycobacterium tuberculosis strains and to investigate cross resistance between two drugs. The agar dilution method was performed for detection of MICs of rifabutin and rifampicin for 112 M. tuberculosis strains obtained from patients with active pulmonary tuberculosis. Cross resistance between rifampicin and rifabutin was detected in 73.1%. Rifabutin MICs for rifampicin resistant strains were three- to four-fold higher than rifabutin-susceptible and/or -resistant strains' MIC values for rifampicin. Despite having 73% cross-resistance with rifampicin in M. tuberculosis isolates, it was concluded that rifabutin might be a valid component of combination therapy in rifampicin resistant tuberculosis cases when the isolate is tested and detected susceptible to rifabutin.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16167516     DOI: 10.1179/joc.2005.17.4.380

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  8 in total

1.  Molecular detection of rifabutin-susceptible Mycobacterium tuberculosis.

Authors:  Huang-Yao Chen; Ming-Chih Yu; Wei-Lun Huang; Mei-Hua Wu; Yung-Lin Chang; Chien-Rai Che; Ruwen Jou
Journal:  J Clin Microbiol       Date:  2012-03-21       Impact factor: 5.948

2.  Probiotics to prevent the need for, and augment the use of, antibiotics.

Authors:  Gregor Reid
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-09       Impact factor: 2.471

3.  Rifampicin and rifabutin resistance in 1003 Mycobacterium tuberculosis clinical isolates.

Authors:  Maha R Farhat; Jaimie Sixsmith; Roger Calderon; Nathan D Hicks; Sarah M Fortune; Megan Murray
Journal:  J Antimicrob Chemother       Date:  2019-06-01       Impact factor: 5.790

4.  Targeting antibiotic resistance mechanisms in Mycobacterium tuberculosis: recharging the old magic bullets.

Authors:  Liem Nguyen
Journal:  Expert Rev Anti Infect Ther       Date:  2012-09       Impact factor: 5.091

5.  Predicting differential rifamycin resistance in clinical Mycobacterium tuberculosis isolates by specific rpoB mutations.

Authors:  W ElMaraachli; M Slater; Z L Berrada; S-Y G Lin; A Catanzaro; E Desmond; C Rodrigues; T C Victor; V Crudu; M T Gler; T C Rodwell
Journal:  Int J Tuberc Lung Dis       Date:  2015-10       Impact factor: 2.373

6.  Commentary: Rifabutin Resistance Associated with Double Mutations in rpoB Gene in Mycobacterium tuberculosis Isolates.

Authors:  Sandeep Sharma; Noton K Dutta
Journal:  Front Microbiol       Date:  2017-11-27       Impact factor: 5.640

7.  Berberine prevents stress-induced gut inflammation and visceral hypersensitivity and reduces intestinal motility in rats.

Authors:  Zhi-Chao Yu; Yong-Xin Cen; Ben-Hua Wu; Cheng Wei; Feng Xiong; De-Feng Li; Ting-Ting Liu; Ming-Han Luo; Li-Liangzi Guo; Ying-Xue Li; Li-Sheng Wang; Jian-Yao Wang; Jun Yao
Journal:  World J Gastroenterol       Date:  2019-08-07       Impact factor: 5.742

8.  Global access of rifabutin for the treatment of tuberculosis - why should we prioritize this?

Authors:  Neesha Rockwood; Maddalena Cerrone; Melissa Barber; Andrew M Hill; Anton L Pozniak
Journal:  J Int AIDS Soc       Date:  2019-07       Impact factor: 5.396

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.